This plus two further intrafemoral applications of fibronectin led to a significant reduction of leukocytes in peripheral blood (P = 0.0096; Fig. 6a) and significant survival prolongation (P = 0.0246; Fig. 6b) in mice with BCR-ABL1T315I+ CML compared with controls. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.